Emergent Plummets as FDA Inspects J&J Vaccine Production Site
Riley Griffin, Bloomberg News The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. , Photographer: Tasos Katopodis/Getty Images
(Bloomberg) Emergent BioSolutions Inc. shares plunged after U.S. regulators told the company to stop making Johnson & Johnsonâs Covid-19 vaccine at a company facility where 15 million doses of an ingredient used in the vaccine had to be discarded.
The U.S. Food and Drug Administration on April 12 initiated an inspection of a Baltimore-based Emergent facility responsible for making the underlying drug substance in the vaccine. Four days later, the FDA asked Emergent to stop making new materials there and to quarantine existing materials until the inspection and any remediation are concluded, according to a company filing on Monday.
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.